World Congress on Industrial Biotechnology May, 2014 1
The Value Proposition Leader in precision gene editing RTDS Non transgenic, non GMO platform RTDS Broadly applicable across many organisms Significant commercial potential 3 high growth verticals >$100 Billion Products launching 2015 Extensive IP portfolio We put precision into gene editing 2
RTDS Rapid Trait Development System A patented site specific mutation technology that can be used to alter microbes, plants or other organisms non transgenically with unparalleled precision. Industrial Biotech 24 employees (6 PhDs, 1 MD) Wholly owned subsidiary of Cibus Global Agriculture trait development 82 employees (21 PhDs ) Over 170 patents and pending patent applications 3
Leveraging RTDS in Three Distinct Verticals Industrial Biotech Agriculture Health & Wellness Company Nucelis Cibus Nucelis Timing Today Mid Term Longer Term Addressable Market Size ~$48 Billion ~$15 Billion ~$45 Billion Margins Moderate to High High Very High Broad Commercial Focus Cosmetic Ingredients Food Ingredients Flavors and Fragrances Input Traits Abiotic Traits Output Traits Other Traits Gene Therapy Pharmaceutical Intermediates Animal Therapeutics 4
Target Markets for Nucelis in Industrial Biotechnology GMO sensitive markets High value bio based specialty products and ingredients Cosmetic Ingredients Flavors and Fragrances Food Ingredients 5
Business Model Nucelis Partner New Product Existing Process In house product development and scale up Third party commercial production Distribution partners Product pipeline Sales Collaborate with Industry leaders Expand product pipeline and expertise Royalties, Milestones, R&D Funding Partner based strain improvement and development Optimize partner commercial strains Royalties, Milestones, R&D Funding 6
Rapid Trait Development System (RTDS) Non GMO, non transgenic Highly precise, site specific RTDS Only targeted base pair is changed No residual foreign DNA Uses the cell s natural DNA repair Oligonucleotide directed mutagenesis Successfully applied to multiple organisms 7
The RTDS Revolution in Perspective 1860s 1910s 1980s 1990s Today Plant Breeding Mutagenesis Marker Assisted Selection Transgenic Gene Modification RTDS Non GMO Lacks precision Non GMO Lacks precision Non GMO Lacks precision GMO Lacks precision Non GMO Very precise 8
Breakthrough in Precision Gene Editing Model Plant System 9.00 > 60 fold improvement 8.00 Improved Conversion Efficiency 7.00 6.00 5.00 4.00 3.00 2.00 1.00 0.00 Original Conversion Current Conversion Continuous Improvement Over Time Source: Company data. 9
Broad Applicability Across Multiple Organisms Yeast & Other microorganisms Nucelis Successful implementation of RTDS in Yeast and Bacteria Proof of concept work in algae and fungi Initial products include squalane, ergosterol, and Vitamin D2 In negotiations on partner based development projects Yeast Bacteria Algae Fungi Agricultural Crops Cibus Agricultural input trait development Herbicide resistance, reduced disease susceptibility, improved stress tolerance, reduced fertilizer requirement, improved nutritional value Herbicide tolerant canola about to enter the US market OSR (Canola) Cassava Maize Flax Potato Sorghum Rice Sugarbeet Sunflower Wheat 10
Cibus Global IP Portfolio and Regulatory Status 200 Holds over 70 issued patents and 100+ patent applications worldwide Technology and traits protected by 8+ patent families RTDS is non GMO compliant in US and EU 180 Number of patents and patent applications 160 140 120 100 80 60 40 20 0 2006 2007 2008 2009 2010 2011 2012 2013 11
Nucelis Squalane Commercialization Yield Improvement from Baseline [%] Yield 14000 12000 10000 8000 6000 4000 2000 0 Jul 2009 Aug 2010 Sep 2011 Oct 2012 Nov 2013 Dec 2014 Date Non GMO process High purity Sustainable process Predictable supply Green feedstock Ergosterol co product Vitamin D2 co product Toll manufacturing with 3 rd party To be commercialized in 2015 12
Human and Animal Health Therapeutics RTDS has potential to be applied to human and animal cell lines, creating disruptive and unique therapeutic solutions to currently incurable genetic disorders. Early targets include high profile and orphan diseases in infectious disease, hematology, cancer, and metabolic disorders. Proof of Concept research has begun on selected targets, with data available in late 2014. 13
Non GM Technology High value products with significant commercial potential Products launching in 2015 We are seeking an expansion of our current investor base and industry partners focused on commercialization. 14